The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy

Agnarsson, Hjálmar Ragnar; Johannsson, Gudmundur; Ragnarsson, Oskar

doi:10.1210/jc.2013-3851

Cited by 9 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В открытом проспективном исследовании Agnarsson и соавт. [78] 175 пациентов с дефицитом ГР в рамках гипопитуитаризма, из которых 98 имели ВНН и получали заместительную терапию кортизона ацетатом (60%) и гидрокортизоном (40%) со среднесуточной эквивалентной дозой гидрокортизона 20,9±5,0 мг, различий в МПК в ПОП и шейке бедренной кости у больных с и без ВНН не выявлено. В исследовании все пациенты в течение 2 лет получали терапию рекомбинантным ГР (дозы ГК за этот период статистически значимо не изменились).…”

Section: влияние заместительной терапии рекомбинантным гормоном ростаunclassified

Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review

et al. 2020

View full text Add to dashboard Cite

Adrenal insufficiency (AI) is a syndrome caused by disturbance in the synthesis and secretion of hormones of the adrenal cortex, which ensure the vital activity, energy and water-salt homeostasis. The widest hormonal deficiency is observed in primary hypocorticism, when the synthesis of not only glucocorticoids (GC) and adrenal androgens, but also mineralocorticoids is disrupted. Lifelong replacement therapy with GCs for this pathology may be associated with a risk of bone loss and osteoporosis. However, at present, there are no clear guidelines for diagnosis of bone condition, including and bone mineral density (BMD) monitoring during treatment with GCs in patients with AI. This review summarizes collected data on the key pathogenetic links of glucocorticoid-induced osteoporosis, incidence of decreased BMD and fractures in patients with AI. In this review factors that influence bone metabolism in this cohort of patients are considered: the type and the dose of prescribed GCs, the type (primary, secondary, HH in congenital adrenal cortex dysfunction) and the duration of AI, age, gender, and the presence of concomitant endocrine disorders (hypogonadism, growth hormone (GH) deficiency). In addition, the review presents data on the effect of adrenal androgen replacement therapy and recombinant GH therapy on bone metabolism in secondary AI.

show abstract

Section: влияние заместительной терапии рекомбинантным гормоном ростаunclassified

Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several human diseases are caused by some deficiencies of hormonal peptides, and hormonal replacement therapy has been an effective treatment method in clinic [32,33]. ELA acts as a new hormonal peptide and plays a key role in heart development.…”

mentioning

confidence: 99%

ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor

Xie¹,

Lv²,

Chen³

2014

ABBS

View full text Add to dashboard Cite

Risks and Benefits of Growth Hormone Replacement in the Elderly

Labadzhyan

Melmed²

2022

Pituitary Disorders Throughout the Life Cycle

View full text Add to dashboard Cite

The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy

Abstract: GH replacement therapy for 2 years increased BMD in hypopituitary patients. In contrast to our hypothesis, GC-insufficient patients receiving near physiological doses of hydrocortisone do not show a greater therapeutic response to GH therapy than their GC-sufficient counterparts.

Cited by 9 publications

References 27 publications

Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review

Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review

ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor

Risks and Benefits of Growth Hormone Replacement in the Elderly

Contact Info

Product

Resources

About